MK-677 vs CJC-1295
MK-677 (Ibutamoren) and CJC-1295 both elevate growth hormone levels, but through entirely different mechanisms and routes. MK-677 is technically not a peptide -- it's a non-peptide ghrelin mimetic taken orally. CJC-1295 is a GHRH analog that requires injection. This distinction significantly affects their use profiles.
Side-by-Side Comparison
| Category | MK-677 | CJC-1295 |
|---|---|---|
| Mechanism of action | Non-peptide ghrelin receptor (GHS-R1a) agonist. Stimulates GH release by mimicking hunger hormone ghrelin. Also increases appetite and can raise cortisol and prolactin slightly. | GHRH analog that binds pituitary GHRH receptors. The DAC modification extends half-life to ~8 days. Amplifies natural GH pulsatility without ghrelin-related side effects. |
| Primary research area | GH deficiency, muscle wasting, bone density, sleep quality. Studied for age-related GH decline and body composition. | GH deficiency, body composition, anti-aging. Studied for sustained IGF-1 elevation and improved GH profiles. |
| Evidence level | Multiple human clinical trials including a 2-year study in elderly subjects (Nass et al., 2008). Published human data on GH, IGF-1, body composition, and bone density. Not FDA-approved. | Phase II clinical trials (ConjuChem). Published human pharmacokinetic data. Less long-term human data than MK-677. Not FDA-approved. |
| Administration route | Oral (capsule or liquid). One of the few GH secretagogues that works orally. | Subcutaneous injection. DAC version once weekly, no-DAC version 1-3x daily. |
| Typical research dosing | 10-25 mg orally once daily, typically before bed. Can be used long-term (studies up to 2 years). | DAC version: 2 mg once weekly subcutaneous. No-DAC: 100 mcg 1-3x daily. |
| Key studies/evidence | Nass et al. (2008) — 2-year study in healthy elderly showing sustained IGF-1 elevation. Murphy et al. (1998) — body composition improvements. Multiple published human trials on GH secretion patterns. | Teichman et al. (2006) — human PK showing sustained IGF-1 increase for 6+ days. ConjuChem phase II trials. Less published human data overall compared to MK-677. |
Can They Be Stacked?
Can be combined since they work through different receptor pathways (ghrelin vs GHRH). The rationale is additive GH release through dual stimulation. This is a common combination in the peptide community, though no published studies examine this specific stack.
Verdict
MK-677 has more published human data (including a 2-year study) and the significant advantage of oral dosing. However, it mimics ghrelin, which can increase appetite, cortisol, and prolactin. CJC-1295 provides a cleaner GH elevation profile through the GHRH pathway without appetite stimulation, but requires injection. MK-677 is better studied for long-term use; CJC-1295 may be preferred by those wanting to avoid ghrelin-related side effects.
Related Comparisons
CJC-1295 and Ipamorelin are both growth hormone secretagogues, but they work through different receptor pathways. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog, while Ipamorelin is a growth hormone-releasing peptide (GHRP). They are frequently combined rather than used as alternatives.
CJC-1295 vs SermorelinCJC-1295 and Sermorelin are both GHRH analogs that stimulate growth hormone release through the same receptor pathway. The key difference is that Sermorelin was the first GHRH analog with decades of clinical use, while CJC-1295 is a newer modified version designed for a much longer half-life.
Ipamorelin vs MK-677Ipamorelin and MK-677 both stimulate growth hormone release through ghrelin-related pathways, but with important differences in selectivity and side effect profiles. Ipamorelin is a true peptide requiring injection, while MK-677 is a non-peptide small molecule taken orally.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.